A detailed history of N Verses Capital, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, N Verses Capital, LLC holds 600 shares of CGEM stock, worth $7,332. This represents 0.0% of its overall portfolio holdings.

Number of Shares
600
Holding current value
$7,332
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$16.03 - $20.86 $9,618 - $12,516
600 New
600 $10 Million

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $557M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track N Verses Capital, LLC Portfolio

Follow N Verses Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of N Verses Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on N Verses Capital, LLC with notifications on news.